Xiaohui H. Suo

Handan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia

Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: May 20, 2026

Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation.

Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation.

Journal: Blood cancer journal

Published: April 06, 2026

Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia.

Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 06, 2026

Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.

Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.

Journal: British journal of haematology

Published: March 19, 2025

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia.

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia.

Journal: Blood cancer journal

Published: September 24, 2024

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.

Journal: Hematological oncology

Published: July 23, 2024

Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study

Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: May 08, 2024

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Journal: Blood

Published: March 22, 2024

Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.

Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 19, 2024

Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.

Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.

Journal: Cancer medicine

Published: January 16, 2024

To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia

To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 04, 2023

Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone

Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone

Journal: Zhonghua nei ke za zhi

Published: December 03, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026